Medicine details
| Image |  |
| Name | Nomigra 50 |
| Dosage | Tablet |
| Generic Name | Sumatriptan |
| Classes |
Analgesic / Pain Killer Central Nervous System Agent Antimigraine Agent |
| Diseases |
Cluster Headache CNS Disorder Migraine |
| Company | Ambee Pharmaceuticals Ltd. |
Drug Package Details
| Strength | 50 mg |
| Storage Condition | |
| Origin Country | Bangladesh |
| Commercial Pack | 4 |
| Price per pack | ৳ 180.68 |
| Cost per pack | ৳ 159.00 |
| Package unit | 10 tabs strip |
| Price per unit | ৳ 45.17 |
| Cost per unit | ৳ 39.75 |
| Discount | 0 |
| Coupon | |
| Remarks |
Sumatriptan
Sumatriptan is a 5-HT1B/1D receptor agonist used to treat migraine. Sumatriptan's therapeutic activity in migraine is most likely due to agonist effects at 5-HT1B/1D receptors on extracerebral, intracranial blood vessels that dilate during a migraine attack, as well as nerve terminals in the trigeminal system. When these receptors are activated, cranial vessels constrict, neuropeptide release is inhibited, and transmission in trigeminal pain pathways is reduced.
Sumatriptan is indicated for the acute treatment of migraine with or without aura in adults.
Tablets:
- Sumatriptan Tablets are available in doses of 25 mg, 50 mg, and 100 mg. Doses of 50 mg and 100 mg may be more effective than the 25-mg dose, but doses of 100 mg may not be more effective than the 50-mg dose. Higher doses may increase the risk of adverse reactions.
- A second dose should only be considered if some response to the first dose was observed. Separate doses by at least 2 hours.
- Maximum dose in a 24-hour period: 200 mg.
- Maximum single dose should not exceed 50 mg in patients with mild to moderate hepatic impairment.
Nasal Spray:
- Sumatriptan is also available as nasal spray. The usual single dose is 10 mg and the maximum daily dose is 30 mg. The doses should be spaced by at least one hour.
The most common side effects associated with sumatriptan are-
- Nausea
- Asthenia
- Sleepiness/ drowsiness/ somnolence
- Tingling or burning feeling (paresthesia)
- Headache
- Dry mouth
- Sumatriptan should only be used where a clear diagnosis of migraine has been established.
- Sumatriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease because this class of compounds (5-HT1B/1D agonists) has the potential to cause coronary vasospasm.
- As with other 5-HT1B/1D agonists, sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported after treatment with Sumatriptan.
- Within a few hours of receiving Sumatriptan, serious adverse cardiac events, including acute myocardial infarction, have been reported.
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients receiving other 5-HT1 agonists, with some resulting in death.
- Significant increases in systemic blood pressure, including hypertensive crisis, have been reported in patients with and without a history of hypertension treated with other 5-HT1 agonists on rare occasions.
- Triptans, including Sumatriptan, have been linked to the development of a potentially fatal serotonin syndrome.
Contraindication
- Sumatriptan is contraindicated in patients who are hypersensitive to Sumatriptan or any of its ingredients.
- Sumatriptan should not be administered within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like-
None known.
Sumatriptan should not be given to patients with-
- ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease.
- uncontrolled hypertension.
- hemiplegic or basilar migraine.
Bangla
English